Krishna Institute of Medical Sciences Limited (NSE:KIMS)
670.10
+6.35 (0.96%)
Nov 21, 2025, 3:30 PM IST
NSE:KIMS Revenue
Krishna Institute of Medical Sciences had revenue of 9.61B INR in the quarter ending September 30, 2025, with 23.59% growth. This brings the company's revenue in the last twelve months to 34.02B, up 25.74% year-over-year. In the fiscal year ending March 31, 2025, Krishna Institute of Medical Sciences had annual revenue of 30.35B with 21.49% growth.
Revenue (ttm)
34.02B
Revenue Growth
+25.74%
P/S Ratio
7.88
Revenue / Employee
6.46M
Employees
5,264
Market Cap
268.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 30.35B | 5.37B | 21.49% |
| Mar 31, 2024 | 24.98B | 3.01B | 13.67% |
| Mar 31, 2023 | 21.98B | 5.47B | 33.13% |
| Mar 31, 2022 | 16.51B | 3.21B | 24.13% |
| Mar 31, 2021 | 13.30B | 2.07B | 18.46% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Biocon | 164.76B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |